Multiple-dose Pharmacokinetics Study of "SYN006 HFA MDI" Administered Orally to Healthy Volunteers
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Budesonide + Procaterol HFA MDI is a novel asthma product containing both budesonide and
procaterol in a single inhaler. Budesonide is a corticosteroid that treats underlying airway
inflammation in asthma. Procaterol is a direct acting sympathomimetic with predominantly
Beta-adrenoceptor stimulant activity selective to Beta-2 receptors (a Beta-2 agonist). It is
used as a bronchodilator in the management of reversible airways obstructive pulmonary
disease. Budesonide and Procaterol therefore have complementary effects, treating two
different components of asthma.